MediciNova, Inc.
MNOV
NASDAQ·Healthcare·Biotechnology·Mkt cap $80.2M
$1.63
▲ +0.62%
P/E
-6.96
Mkt Cap
$80.2M
52-Wk Range
$1.17–$1.96
52-Week Range
$1.17 - $1.96
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 29.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Differentiated small molecule pipeline addressing unmet medical needs
- Strategic partnerships with established pharmaceutical companies
- Oral bioavailability focus enabling patient accessibility
- Multi-indication development approach reducing single-asset risk
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Mild headwinds expected
Clinical trial progress and potential FDA approvals for MN-166 in multiple indications
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+24.4% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying MNOV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 13, 2026
Reported EPS of -$0.05 vs -$0.06 consensus (+21.1% surprise). Revenue of $459.0K vs $75.0K expected (+512.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+21.1%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$0
$0
$0
$0
$134.6K
$123.3K
$151.7K
$187.0K
Margins · last 8Q
Gross
—
Profit
-1383.1%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: D. Boral Capital · May 4, 2026
vs Industry
How MNOV stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.